Laron Syndrome

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

GHR, GH1, IGF1, IGFBP3, STAT5B, BCL2, SOAT1, SLC35G1, DESI1, TXNIP, TGM2, STAT5A, OPA1, PROP1, CASP3, IGHD, GHRHR, EGF, CASP9, SNORA44

Drugs

Mecasermin ( INCRELEX, SOMAZON ), Mecasermin rinfabate ( IPLEX ), Recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3

Interested in hearing about new therapies?

Laron syndrome is a condition that occurs when the body is unable to utilize growth hormone. It is primarily characterized by short stature. Other signs and symptoms vary but may include reduced muscle strength and endurance; hypoglycemia in infancy; delayed puberty; short limbs (arms and legs); and obesity. It is often caused by changes (mutations) in the GHR gene and is inherited in an autosomal recessive manner. Treatment is focused on improving growth and generally includes injections of insulin-like growth factor 1 (IGF-1).